Korea Quantum Computing Co., Ltd. (KQC) announced today that it has signed a joint research and development agreement with Hanlim Pharmaceutical Co., Ltd. to accelerate the discovery of new drug candidates using advanced quantum computing technologies.

Under the agreement, the two companies will collaborate on quantum-enabled drug discovery programs, including molecular simulations, compound screening, and the identification of drug candidates derived from natural products. By integrating their respective technologies, research teams, and infrastructure, the partners aim to significantly improve the speed, accuracy, and efficiency of pharmaceutical R&D.

The signing ceremony was attended by Jung-Jin Kim, CEO of Hanlim Pharmaceutical, Ji-Hoon Kwon, Chairman of KQC, and senior R&D executives from both organizations. The collaboration will leverage quantum computing’s ultra-high-performance computational capabilities to analyze complex molecular interactions and large-scale biomedical data that are difficult to process with conventional computing systems.

Through the partnership, Hanlim Pharmaceutical will apply quantum-based molecular modeling and simulation to its proprietary research data, enabling faster optimization of lead compounds and more precise prediction of drug–target interactions. The companies expect this approach to dramatically reduce both the time and cost required for traditional drug discovery.

“This joint research agreement represents a major step forward for Hanlim Pharmaceutical’s drug development strategy and open innovation efforts,” said Jung-Jin Kim, CEO of Hanlim Pharmaceutical. “We look forward to accelerating our R&D programs through close collaboration with Korea Quantum Computing and its cutting-edge quantum technologies.”

John J.Y. Kim, CEO of Korea Quantum Computing, added, “We are proud to partner with Hanlim Pharmaceutical to advance next-generation drug discovery. By combining Hanlim’s pharmaceutical expertise with KQC’s quantum computing capabilities, we aim to deliver meaningful breakthroughs in biomedical research and contribute to the future of precision medicine.”

With this agreement, the two companies seek to establish a new model for quantum-powered pharmaceutical innovation in Korea.